Meeting
2023 ASCO Genitourinary Cancers Symposium
Time to event following bacillus Calmette-Guerin therapy initiation in Medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010-2019.
Authors
Allison A. Petrilla
Inovalon, Inc., Bowie, MD
Allison A. Petrilla , Alison R. Silverstein , Anthony Eccleston , Allison Thompson , Julia Brinkmann , Temitope Bello , Jane Chang , Joseph C Cappelleri , Sanjana Chandrasekar , Amy L Schroeder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 473)
DOI
10.1200/JCO.2023.41.6_suppl.473
Abstract #
473
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.
First Author: Corbin J. Eule
Poster
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
First Author: Joseph M Jacob
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes of metastasis-directed therapy for solitary sites of metastatic clear cell renal cell carcinoma.
First Author: Akeem Ronell Lewis